These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24464755)

  • 21. Myocardial Deformation Analysis in
    Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of Autophagy Ameliorates Cardiomyopathy in
    Singh SR; Zech ATL; Geertz B; Reischmann-Düsener S; Osinska H; Prondzynski M; Krämer E; Meng Q; Redwood C; van der Velden J; Robbins J; Schlossarek S; Carrier L
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29021349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.
    Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G
    Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations.
    van Dijk SJ; Boontje NM; Heymans MW; Ten Cate FJ; Michels M; Dos Remedios C; Dooijes D; van Slegtenhorst MA; van der Velden J; Stienen GJ
    Pflugers Arch; 2014 Aug; 466(8):1619-33. PubMed ID: 24186209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
    Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
    Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy.
    Helms AS; Tang VT; O'Leary TS; Friedline S; Wauchope M; Arora A; Wasserman AH; Smith ED; Lee LM; Wen XW; Shavit JA; Liu AP; Previs MJ; Day SM
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31877118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
    Suay-Corredera C; Alegre-Cebollada J
    FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
    Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertrophic cardiomyopathy mutations in
    Toepfer CN; Wakimoto H; Garfinkel AC; McDonough B; Liao D; Jiang J; Tai AC; Gorham JM; Lunde IG; Lun M; Lynch TL; McNamara JW; Sadayappan S; Redwood CS; Watkins HC; Seidman JG; Seidman CE
    Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
    Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
    J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. E258K HCM-causing mutation in cardiac MyBP-C reduces contractile force and accelerates twitch kinetics by disrupting the cMyBP-C and myosin S2 interaction.
    De Lange WJ; Grimes AC; Hegge LF; Spring AM; Brost TM; Ralphe JC
    J Gen Physiol; 2013 Sep; 142(3):241-55. PubMed ID: 23980194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
    Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
    J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.
    Smelter DF; de Lange WJ; Cai W; Ge Y; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1179-H1191. PubMed ID: 29451820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
    Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
    J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
    Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
    BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.
    Glazier AA; Thompson A; Day SM
    Pflugers Arch; 2019 May; 471(5):781-793. PubMed ID: 30456444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.